Mesothelioma Stages: Stage 1, 2, 3 & 4 Explained

Staging Systems

Mesothelioma staging describes how far the cancer has spread. The most widely used system for pleural mesothelioma is the TNM system (Tumor, Node, Metastasis), which was updated by the International Mesothelioma Interest Group (IMIG). Peritoneal mesothelioma uses a different system called the Peritoneal Cancer Index (PCI).

Staging is determined through imaging tests (CT, PET, MRI), biopsies, and sometimes exploratory surgery.

Stage 1: Localized

In Stage 1, mesothelioma is confined to one area of the pleura (or peritoneum) and has not spread to lymph nodes or distant organs. This is the earliest and most treatable stage.

• Stage 1A: Cancer is in the outer layer of the pleura only
• Stage 1B: Cancer has spread to the inner pleural layers but not beyond

Stage 2: Regional Spread

In Stage 2, the tumor has grown and may have spread to nearby lymph nodes or adjacent structures like the diaphragm or lung tissue. Surgery may still be an option, though outcomes are less favorable than Stage 1.

Median survival: approximately 19 months with treatment.

Stage 3: Extensive Spread

Stage 3 is divided into 3A and 3B. The cancer has spread more extensively to regional lymph nodes and may have invaded nearby organs. Surgery is generally not curative at this stage, but palliative surgery may be performed to relieve symptoms.

Median survival: approximately 16 months with treatment.

Stage 4: Distant Metastasis

In Stage 4, mesothelioma has spread to distant organs such as the liver, kidneys, brain, or bones. Treatment focuses on managing symptoms and improving quality of life rather than curative intent. Clinical trials may offer additional options.

Median survival: approximately 12 months.

Treatment by Stage

Why Staging Matters

Staging is the process of determining how far a cancer has spread from its original location. For mesothelioma, staging is critical because it guides treatment decisions, provides prognostic information, and is relevant for legal claims. Patients with early-stage disease may be candidates for aggressive surgical treatment that can significantly extend survival, while patients with advanced disease are typically treated with systemic therapies or palliative care. Understanding the staging system helps patients and families make informed decisions about treatment options.

The staging of mesothelioma is more complex than for many other cancers because mesothelioma grows along the surface of the pleura or peritoneum rather than forming a discrete mass. This diffuse growth pattern makes it difficult to define the boundaries of the tumor and to determine precisely how far it has spread. Staging is performed using a combination of imaging studies (CT, PET, MRI) and, in some cases, surgical exploration.

The TNM Staging System for Pleural Mesothelioma

The most widely used staging system for pleural mesothelioma is the TNM system, developed by the International Association for the Study of Lung Cancer (IASLC). The TNM system evaluates three components: the primary tumor (T), lymph node involvement (N), and distant metastases (M). Each component is assigned a number or letter that reflects the extent of disease, and these are combined to produce an overall stage from I to IV.

Stage I disease is localized to the pleura on one side of the chest, without lymph node involvement or distant spread. Stage II involves limited spread to the lung, diaphragm, or pericardium on the same side. Stage III involves more extensive local spread, including invasion of the chest wall, mediastinum, or lymph nodes on the same side. Stage IV involves distant metastases, spread to the opposite chest, or involvement of distant lymph nodes. Patients with Stage I or II disease are generally better candidates for surgery than those with Stage III or IV disease.

Staging for Peritoneal Mesothelioma

Peritoneal mesothelioma does not have a universally accepted formal staging system analogous to the TNM system for pleural disease. Instead, the extent of peritoneal disease is often assessed using the Peritoneal Cancer Index (PCI), which divides the abdomen into 13 regions and assigns a score to each based on the size of tumor deposits. The total PCI score (ranging from 0 to 39) is used to assess the feasibility of cytoreductive surgery — patients with lower PCI scores are generally better candidates for complete cytoreduction with HIPEC.

The PCI score is determined during surgical exploration, which means that the full extent of peritoneal disease is often not known until the patient is in the operating room. This is one reason why the decision to proceed with cytoreductive surgery for peritoneal mesothelioma requires careful patient selection and should be made by surgeons with extensive experience in this procedure.

How Staging Affects Legal Claims

The stage of mesothelioma at diagnosis is relevant to legal claims in several ways. More advanced disease generally correlates with higher medical expenses, greater lost income, more severe pain and suffering, and shorter life expectancy — all of which affect the calculation of damages. Patients diagnosed at an early stage who are candidates for aggressive treatment may have higher medical expenses (due to the cost of surgery and multimodal therapy) but longer survival, which affects the calculation of future lost income and ongoing medical costs.

Staging information is also relevant to the timing of legal proceedings. Courts give priority to mesothelioma patients who are seriously ill, and a Stage IV diagnosis may support a request for expedited scheduling. An experienced mesothelioma attorney will use the staging information to build the strongest possible case for maximum compensation.

Frequently Asked Questions